We are monitoring the impact of COVID-19 on Asia Pacific Immunotherapy Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1095
Share on
Share on

Asia Pacific Immunotherapy Drugs Market Research Report – Segmented By Drug Type, Application & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, Growth & Forecast | 2021 to 2026

Pulished: April, 2021
ID: 1095
Pages: 145

Asia Pacific Immunotherapy Drugs Market Size & Growth (2021 to 2026):

As per our report, the Asia Pacific Immunotherapy Drugs Market size is estimated to worth USD 23.72 billion by 2026 and USD 13.16 billion in 2021, growing at a tremendous CAGR of 12.5% from 2021 to 2026.

The rising prevalence of target diseases, increased demand for monoclonal antibodies and biosimilars, increasing use of immunotherapy medications over traditional therapies, and a favourable approval scenario are all contributing to the Asia Pacific market's growth. Monoclonal antibodies are beneficial because they allow researchers to create antibodies that target a single tumour antigen. The broad use of personalized medicine technologies will be influenced by a number of factors, including growing education at the intersection of engineering and medicine, as well as guidelines that encourage innovative clinical trial designs and the adoption of electronic medical records (EMR). The rising frequency of lifestyle diseases in the region is fueling the expansion of the immunotherapy medications industry. In addition, the growing use of targeted therapeutics for a variety of disorders is expected to propel the market forward. Activation immunotherapies and suppression immunotherapies are two types of immunotherapy. In the next few years, favourable government measures are also projected to enhance market growth. Low manufacturing costs and a simpler regulatory environment are the key growth drivers in the APAC area. To totally treat cancer, this sort of therapy directly targets the causes of cancer, such as genes, proteins, and the tissue environment. Targeted therapy targets cancer cells while leaving healthy cells alone.

The growing use of such procedures, particularly in this country, is expected to improve the overall market for immunotherapy. Market expansion will be aided by current nanotechnology advancements in immunotherapy. The nanoparticles, which are smaller than 100 nanometers in size, were created to treat cancer. Active or passive drug assault, high solubility bioavailability, and multifunctionality are among the advantages provided.

Market growth is expected to be restricted by timeline challenges, side effects, manufacturing complexities, and a high attrition rate during the product development cycle. The market expansion is hampered by the high cost of immunotherapy treatment and a greater attrition rate during the product development cycle. However, various restrictions and difficulties are expected to limit the Immunotherapy Drugs Market's growth. Immunotherapy treatment is seen as too expensive by the general public, and the availability of alternative treatments is seen as a key impediment to the immunotherapy drug market's expansion.

This research report on the Asia Pacific Immunotherapy Drugs Market has been segmented and sub-segmented into the following categories:

By Drug Type: 

  • Monoclonal Antibodies
  • Interferons
  • Interleukins
  • Vaccines
  • Checkpoint Inhibitors

By Application: 

  • Blood Cancer
  • Cervical Cancer
  • Breast Cancer
  • Glioblastoma
  • Lung Cancer
  • Gastric Cancer
  • Prostate Cancer
  • Melanoma

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The APAC region is the fastest-growing region in the global immunotherapy drugs market. There has been a huge increase in the number of people diagnosed with various types of cancer. One of the most significant risk factors for cancer is smoking. The incidence of cancer is increasing as a result of a deteriorating lifestyle, smoking, and drinking.

During the forecast period, the Indian immunotherapy drugs market is estimated to grow at the highest CAGR. The Asia Pacific immunotherapy industry is expected to grow due to an increase in cancer patients. Different treatments are available on the market, however immunotherapy has the advantage of being more effective than other treatments.

The Chinese immunotherapy drugs market is another lucrative regional market in the APAC market. This treatment is useful for patients with melanoma cancer who have failed to respond to chemotherapy or other forms of radiation therapy. The market has grown as the government's support for research and development has increased, as has healthcare spending.

KEY MARKET PLAYERS:

A few of the promising companies operating in the Asia Pacific Immunotherapy Drugs Market profiled in this report are Roche, Merck, Eli Lilly, Novartis, AstraZeneca, GlaxoSmithKline PLC, Amgen, Celgene, Bristol Myers Squibb, and Seattle Genetics.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Drug Type                             

                                5.1.1 Monoclonal Antibodies     

                                5.1.2 Interferons             

                                5.1.3 Interleukins            

                                5.1.4 Vaccines  

                                5.1.5 Checkpoint Inhibitors         

                5.2 By Application                           

                                5.2.1 Blood Cancer         

                                5.2.2 Cervical Cancer     

                                5.2.3 Breast Cancer        

                                5.2.4 Glioblastoma         

                                5.2.5 Lung Cancer           

                                5.2.6 Gastric Cancer       

                                5.2.7 Prostate Cancer    

                                5.2.8 Melanoma              

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9. Market Leaders' Analysis                                        

                9.1 Eli Lilly                           

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck                           

                9.3 Roche                           

                9.4 Amgen                         

                9.5 Novartis                       

                9.6 Celgene                       

                9.7 AstraZeneca               

                9.8 Bristol Myers Squibb                              

                9.9 GlaxoSmithKline PLC                              

                9.10 Seattle Genetics                    

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11. Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Immunotherapy Drugs Market By Region, From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Immunotherapy Drugs Market By Drug Type, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific Monoclonal Antibodies Market By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Interferons Market By Region, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Interleukins Market By Region, From 2021 to 2026 (USD Billion)
  6. Asia-Pacific Vaccines Market By Region, From 2021 to 2026 (USD Billion)
  7. Asia-Pacific Checkpoint Inhibitors Market By Region, From 2021 to 2026 (USD Billion)
  8. Asia-Pacific Immunotherapy Drugs Market By Application, From 2021 to 2026 (USD Billion)
  9. Asia-Pacific Blood Cancer Market By Region, From 2021 to 2026 (USD Billion)
  10. Asia-Pacific Cervical Cancer Market By Region, From 2021 to 2026 (USD Billion)
  11. Asia-Pacific Breast Cancer Market By Region, From 2021 to 2026 (USD Billion)
  12. Asia-Pacific Glioblastoma Market By Region, From 2021 to 2026 (USD Billion)
  13. Asia-Pacific Lung Cancer Market By Region, From 2021 to 2026 (USD Billion)
  14. Asia-Pacific Gastric Cancer Market By Region, From 2021 to 2026 (USD Billion)
  15. Asia-Pacific Prostate Cancer Market By Region, From 2021 to 2026 (USD Billion)
  16. Asia-Pacific Melanoma Market By Region, From 2021 to 2026 (USD Billion)
  17. China Immunotherapy Drugs Market By Drug Type, From 2021 to 2026 (USD Billion)
  18. China Immunotherapy Drugs Market By Application, From 2021 to 2026 (USD Billion)
  19. India Immunotherapy Drugs Market By Drug Type, From 2021 to 2026 (USD Billion)
  20. India Immunotherapy Drugs Market By Application, From 2021 to 2026 (USD Billion)
  21. Japan Immunotherapy Drugs Market By Drug Type, From 2021 to 2026 (USD Billion)
  22. Japan Immunotherapy Drugs Market By Application, From 2021 to 2026 (USD Billion)
  23. South Korea Immunotherapy Drugs Market By Drug Type, From 2021 to 2026 (USD Billion)
  24. South Korea Immunotherapy Drugs Market By Application, From 2021 to 2026 (USD Billion)
  25. Australia Immunotherapy Drugs Market By Drug Type, From 2021 to 2026 (USD Billion)
  26. Australia Immunotherapy Drugs Market By Application, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample